Stay updated on Pralsetinib vs Standard of Care in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pralsetinib vs Standard of Care in NSCLC Clinical Trial page.

Latest updates to the Pralsetinib vs Standard of Care in NSCLC Clinical Trial page
- Check3 days agoChange DetectedUpdated to Revision: v3.0.2 (replacing v3.0.1); the 'Back to Top' element was removed, a minor UI change.SummaryDifference0.2%
- Check10 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.2%
- Check18 days agoChange DetectedThe web page has been updated to include new information about a clinical study of pralsetinib for advanced non-small cell lung cancer, including details about the study's design, eligibility criteria, and treatment options.SummaryDifference100%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%
- Check39 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
- Check46 days agoChange DetectedThe web page has been updated to version 2.16.10, and the previous service alert regarding planned maintenance has been removed.SummaryDifference0.9%
Stay in the know with updates to Pralsetinib vs Standard of Care in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pralsetinib vs Standard of Care in NSCLC Clinical Trial page.